119 related articles for article (PubMed ID: 11220350)
1. Sulphonylurea dose-response relationships: relation to clinical practice.
Lindblad U; Melander A
Diabetes Obes Metab; 2000 Jan; 2(1):25-31. PubMed ID: 11220350
[No Abstract] [Full Text] [Related]
2. Sulfonylurea treatment in type 2 diabetes.
Bester K; Ton J; Korownyk C
Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607
[No Abstract] [Full Text] [Related]
3. Can alpha-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus?
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(6):502-7. PubMed ID: 8746620
[TBL] [Abstract][Full Text] [Related]
4. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
5. [Safety is the issue again].
Overbeck P
MMW Fortschr Med; 2013 Oct; 155(17):26. PubMed ID: 24340377
[No Abstract] [Full Text] [Related]
6. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
7. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
Blickle JF; Brogard JM
Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
[No Abstract] [Full Text] [Related]
8. The second-generation sulfonylureas: change or progress?
Kreisberg RA
Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729
[No Abstract] [Full Text] [Related]
9. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
10. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
11. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
12. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
13. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
14. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
15. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
Barry HC
Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
[No Abstract] [Full Text] [Related]
16. [Not Available].
Viardot A
Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
[No Abstract] [Full Text] [Related]
17. Update on oral hypoglycemics (continuing education credit).
White JR
J Pract Nurs; 1994 Mar; 44(1):24-31; quiz 31-3. PubMed ID: 8158562
[No Abstract] [Full Text] [Related]
18. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both?
Khan U; Seetharaman S; Merchant R
Am J Med; 2017 Jan; 130(1):e29-e30. PubMed ID: 27593606
[No Abstract] [Full Text] [Related]
19. A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.
Riddle MC
Diabetes Care; 2019 Dec; 42(12):2161-2163. PubMed ID: 31748210
[No Abstract] [Full Text] [Related]
20. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion.
Adachi H; Yanai H
Diabetes Metab; 2015 Apr; 41(2):176-7. PubMed ID: 25559655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
